Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527520 | 0.86 | GLA (0.61) | GLAEPHX2ALDH1A1HTTCRHBP | |
| SCHEMBL1896218 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL12578570 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL1161063 | 0.83 | THRB (0.47) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL1844621 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL1844624 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL1844620 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL13579581 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| SCHEMBL328838 | 0.83 | GLA (0.42) | GLAALDH1A1HTTCRHBPCRHR2 | |
| Methyl Alcohol SCHEMBL5319479 | 0.81 | HSD11B1 (0.41) | GLAALDH1A1HTTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459548-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | claimed |
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | claimed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | claimed |
| EP-2459548-B1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-19 | — | — | EP | disclosed |
| US-8536173-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11-B-hydroxysteroid dehydrogenase type I | SANOFI (FR) | 2013-09-17 | — | — | US | disclosed |
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165337-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NR2C2, CBR3, NR0B2 | GLA 4545/4885EPHX2 2241/4885ALDH1A1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.